SCHEMBL5070898

SCHEMBL5070898

CCC1CCCCO1.O=S(=O)(O)c1ccccc1

nearest known ligand 0.50

Known targets — ChEMBL curated mechanism

BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 2/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5069254 0.81 TSHR (0.50) ALDH1A1TSHRSMN1; SMN2PKMMEN1
SCHEMBL29028819 0.79 TSHR (0.48) ALDH1A1TSHRSMN1; SMN2PKMMEN1
SCHEMBL28170343 0.77 AOC2 (0.51) ALDH1A1TSHRSMN1; SMN2HPGDCYP2C9
SCHEMBL5070934 0.77 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MEN1KMT2AGAA
SCHEMBL5068381 0.77 TSHR (0.48) ALDH1A1TSHRSMN1; SMN2PKM
SCHEMBL10855433 0.76 SLC12A2 (0.51) ALDH1A1TSHRSMN1; SMN2HPGDMEN1
SCHEMBL28988057 0.76 SMN1; SMN2 (0.52) ALDH1A1TSHRSMN1; SMN2HPGDCYP2C9
SCHEMBL13486887 0.74
SCHEMBL13486886 0.74
SCHEMBL153432 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365215-B2 Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same UBE INDUSTRIES, LTD. (JP) 2008-04-29 US disclosed
US-20070106083-A1 Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same UBE INDUSTRIES, LTD. (JP) 2007-05-10 US disclosed
EP-1661894-A1 PROCESS FOR PRODUCTION OF 4-AMINOTETRAHYDROPYRANS AND SALTS THEREOF WITH ACIDS, INTERMEDIATES FOR THE PROCESS, AND PROCESS FOR PRODUCTION THEREOF Ube Industries, Ltd. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070106083-A1 Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same PAH, HPD, REN ALDH1A1 875/4885TSHR 3997/4885SMN1; SMN2 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.